Neuropathic Ocular Pain (NOP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Neuropathic Ocular Pain (NOP) Market Outlook

Thelansis’s “Neuropathic Ocular Pain (NOP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuropathic Ocular Pain (NOP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuropathic Ocular Pain (NOP) Overview

Neuropathic Ocular Pain (NOP) is caused by a direct injury or functional disturbance of the neural elements involved in detecting and processing nociceptive stimuli. These elements include the peripheral nerve terminals and axons of the nociceptive sensory neurons located in the dorsal root and cephalic sensory ganglia; they also comprise the higher-order neurons of the spinal cord, brain stem, thalamus, and various other subcortical and cortical structures in charge of receiving and processing the peripheral nociceptive input. The abnormal, unpleasant sensation caused by the disturbed functioning of any of the components of the brain pain matrix is called ‘neuropathic pain’ and is typically evoked at the periphery by sensory nerve traumatisms, metabolic diseases such as diabetes, and by the action of a large variety of chemical, toxic, or infectious agents causing damage to peripheral sensory neurons at any point of their trajectory (peripheral neuropathic pain); within the central nervous system, damage to the pain-processing neuronal groups composing the pain network by ischemia, hemorrhage, mechanical compression, infections, or degenerative processes may also lead to central neuropathic Ocular pain.

• The prevalence of Neuropathic Ocular Pain (NOP) ranges from 0.34% to 0.45% of the population aged 35 years and above in the USA. 27% of the total diagnosed population are referred to be chronic, and the rest of the others are diagnosed with acute conditions.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: